Logo - springer
Slogan - springer

Biomedical Sciences - Pharmacology & Toxicology | Pharmaceutical Chemistry Journal

Pharmaceutical Chemistry Journal

Pharmaceutical Chemistry Journal

Editor-in-Chief: Nikolai Shimanovskii

ISSN: 0091-150X (print version)
ISSN: 1573-9031 (electronic version)

Journal no. 11094

$199.00 Personal Rate e-only for the Americas
Get Subscription

Online subscription, valid from January through December of current calendar year

Immediate access to this year's issues via SpringerLink

1 Volume(-s) with 12 issue(-s) per annual subscription

Automatic annual renewal

More information: >> FAQs // >> Policy

Instructions for Authors

Pharmaceutical Chemistry Journal

Journal is a translation of the peer-reviewed Russian journal Khimiko-Farmatsevticheskii Zhurnal.

Manuscript Submission 

Please submit articles here:
For questions concerning to the editorial process or status of submission please contact:
Pharmaceutical Chemistry Journal
(Khimiko-Farmatzevticheskii Zhurnal)
Dmitrovskoe Shosse 157, build.6
127 411 Moscow
Phone: + 7 499 258 0882
Fax: +7 499 258 0828 ext.13
E-mail: chem@folium.ru
Website: http://chem.folium.ru/index.php/chem

Instructions on the preparation of a manuscript in Russian

are available at the following link:

Instructions for Contributions in English  

Papers submitted to Pharmaceutical Chemistry Journal / Khimiko-Farmatsevticheskii Zhurnal should reflect new, previously unreported investigations performed at the modern scientific and technological level and advanced commercial experience in the following fields:
• Molecular biology and biochemistry: isolation of promising pharmacological substances; elucidation of the mechanisms of drug action; establishment of the structure - activity relationships; optimization of the search for new drugs. Problems of generics and biosimilars
• Experiments aimed at obtaining new compounds, including those isolated from medicinal plants, microorganisms, and other life organisms and studying their pharmacological properties, modeling/PK/Simulations, novel QSAR, QSPR on pharmacokinetical and pharmacodynamical properties, using PK prediction-method of specific biological activity.
• Scientific and technological works aimed at the creation of new and the development of existing methods of synthesis of drugs and semi products, with a view to increasing quality of medicinal products; economy of materials, energy, and labor input; increase in the ecological safety and labor conditions by means of rational use of raw materials and wastes, development of waste-free technologies, application of new analytical and control facilities, in particular, automated systems for the control of technological processes, operating equipment, and plants.
• Design of new and modernization of existing equipment for chemico-pharmaceutical plants, microorganisms and other life organisms (including mechanization and automation of dangerous and laborious operations), aiming to increase their technological and economic efficiency.
• Description of the properties and applications of new medicinal products,drug delivery and targeting, multifunctional nanosystems, genomics, proteomics, and metabolonomics of new phramaceutical agents, nanobiotechnology of SiRNA, microRNAs, antibodies and nanoparticles. Application of new physicochemical methods with the goal of uncovering new molecular details of condensed media, molecular-based studies of the control of surface chemistry of solid particles in the micrometer and nanometer range.
• Achievements in domestic and world science and technology of interest for scientists engaged in pharmaceutical chemistry and engineers of chemico-pharmaceutical plants, microorganisms and other lyfe organisms including reviews and brief information on the published literature; Information about scientific meetings, conferences, and exhibitions; Book reviews; Papers for discussion of scientific and technological problems; Urgent publications on important topics as “Letters to Editor” (note: publishing a “Letter to Editor” does not prohibit submitting a detailed paper on the same subject).
The papers should be submitted by authors immediately and creatively participating in the whole work. Participants contributing in separate stages can be mentioned in the text.
Material must be presented in the following order:
1. Papers presenting the results of experiments on the synthesis of new compounds and their characterization should contain separate chemical and biological experimental parts:
a. The experimental chemical part describes the methods of synthesis and analysis of the obtained compounds and describes their physicochemical properties. In particular, this section indicates:
• • the amounts of initial reactants (in grams and moles);
• the sequence and conditions of operations, including isolation and purification stages (temperature, pressure, treatment time, and other parameters);
• data of elemental analyses and physicochemical properties (in a separate table) confirming the proposed structures. When several compounds are obtained using the same method, the procedure has to be described for one compound only;
• data characterizing the comparative properties of a series of compounds (in the form of a table).
b. The experimental biological part indicates:
• the methods of investigation used for determining the biological activity (original methods should be described in detail);
• the types and numbers of experimental animals (these experiments should be performed with observation of all conventional rules established for work with experimental animals);
• the results of tests, with indication of the activity and toxicity of compounds studied in comparison to the analogous reference substances.
In the discussion and conclusion, the paper should (if possible) consider the relationship between structure and activity of the compounds studied and give a conclusion concerning both basic and applied significance of the results.
2. Paper devoted to the development of drug production technology and methods of commercial synthesis, analysis, and control, should describe the following (including separate experimental part):
• newly developed methods and technological processes;
• sequence and conditions of separate stages;
• equipment, devices, instruments, and other technical facilities;
• amounts of charged materials and discharged products, with error limits (for methods of analysis and control);
• other technical and economic data necessary for the reproduction of the proposed methods and processes and evaluation of their efficiency.
3. Papers presenting new medicinal products should compile:
• data on the chemical and physical properties;
• molecular and structural formulas;
• main results of the biological tests and clinical investigations;
• data on the administration doses, indications and counter indications;
• other data corresponding to the conventional instruction for use, with indication of the registration certificate numbers and available forms of a given drug
4. New substances (isolated or synthesized) should be given names in accordance with recommendations of the International Union of Pure and Applied Chemistry (IUPAC) and the International Union of Biochemistry (IUB). Enzymes should be named in accordance with the IUB catalog, with the corresponding enzyme number indicated in square brackets. Indicate Latin names of plants and microorganisms.
5. The paper should be provided with recommendations concerning the possibility of using the results in basic research and / or practice.

Manuscript Form 

The manuscript must typically not exceed 8 – 10 typeset pages (1.5-spaced, font size 12), including the title page, references, tables, figures with captions, photographs, and any appendixes. The volume of review papers can be increased to 18 – 20 pages.
The title page should contain a concise but informative title, initials and surnames of all the authors (in Russian and English), the names of institutions (without abbreviations), and their locations (city, country).
The manuscript should be neatly typed (1.5-spaced, font size 12).
Acceptable file formats include .doc, .docx, .rtf, and .dvi. Please do not upload .pdf files. Your manuscript will be converted to a .pdf file by our submission management program, Editorial Manager.
Cover Letter
Each manuscript should be accompanied by a cover letter addressed to the Editor, and signed by the corresponding author on behalf of all authors. The cover letter should explicitly state that the manuscript has not been previously published in any language anywhere and that it is not under simultaneous consideration by another journal. The cover letter should also disclose if the manuscript has been previously rejected either by Pharmaceutical Сhemistry Journal or another journal and should include a justification for resubmission.
The cover letter for the Editor should contain the full address (with zip code), phone number (work and /or home), and e-mail of the author to whom all correspondence from the Editor should be sent.
Research Papers require a structured abstract of 200 words or less. It should
contain the information about purpose, methods, results and conclusions.
For all manuscripts, please provide a list of no more than 5 keywords.

Formulas, Terms, Units of Measure

Use commonly accepted physical, chemical, technical, and mathematical terms, units of measure, and notations. Abbreviations of the units should follow recommendations of the International Union of Pure and Applied Chemistry (IUPAC).
Equations should be numbered with Arabic numerals in parentheses on the right.
Chemical compounds should be given full names (according to IUPAC Nomenclature) and denoted by Roman numerals in parentheses (the same Roman numerals without parentheses are used with incomplete names).
Equipment, instruments, and other technical facilities, as well as special materials used in the work should be given with indication of the model type, manufacturer, and country (e.g., JEM 100 electron microscope (JEOL, Japan)). The original (named) reactions and methods should be given in original transcription (e.g., Lowry method).
Typical examples of using abbreviations for methods and data presentation are as follows:
Compound I: yield, 2.55 g (84.9 %); b.p., 52 °C/10 Torr; b.p., 78 °C (reported: 77°C [5]); , +8.2° (c, 2.01; EtOH); , 0.8703; , 1.5814; Rf, 0.44; MR D, 45.07 (calcd., 45.12).
UV spectrum in C2H5OH [λ]max, nm (log ε)]: 220 (4.34), 248 (4,6), 313 (4.0).
IR spectrum (νmax,cm– 1): 1506 (N=N), 1752 (C–O), 3312 (C–O).
1H NMR spectrum in DMSO-d6 (δ, ppm): 8.05 (dd, 1H, J1 1.2 Hz, J2 5.0 Hz, NH), 7.20 – 7.00 (m, 4H, C6 H4) 6.63 (d, 1H, J 5.05 Hz, 4-H).
Mass spectrum, m/z (I rel, %): 318 (100) [M]+, 300 (10), 276 (67), 273 (40), 227 (11), 91 (85). Example of the results of elemental analysis Found (%): C, 52.94; H, 6.85; N, 8.45; C42H63Br3N2O5.
Anal. calcd. (%): C, 53.67; H, 6.71; N, 8.95. (Elements are arranged in the following order: C, H, Br, Cl, F, I, N, O, P, S, and so on).
Use the following abbreviations of units frequently encountered in the text:
second (unit of time) sec
liter (unit of volume) liter
milliliter ml
microliter μl
micron μm
gram-molecule mole
Melting and boiling points of substances in the text and table headings are denoted as m.p. and b.p., respectively.
Orientations of substituents in chemical compounds are written in italic: ortho- (o-), metha- (m-), para- (p-), trans-, cis-, gauche-, sec-, tert-, E-, Z-, R-, S-, L-, D-, etc.
Avoid excessive use of abbreviations overloading the text. The first use of abbreviations in the text should be clearly explained.
The following common abbreviations can be used without such explanations: UV (ultraviolet), IR (infrared), NMR (nuclear magnetic resonance), TLC (thin layer chromatography), GC (gas chromatography); DTA (differential thermal analysis), HPLC (high-performance liquid chromatography).


The figure axes should be parallel to the paper edges. The letter notation should be generally the same as that in the text of the manuscript. The coordinate axes should be provided with names or symbols of the corresponding variables ad the units of measure (conventionally abbreviated) separated by comma. For example, in presenting spectroscopic data for the UV and visible spectral range, the abscissa indicates wavelength (λ, nm) and the ordinate gives molar extinction (lg ε); for the IR and Raman spectra, the abscissa indicates wave number (ν, cm – 1 ) and the ordinate shows the percentage transmission (e.g., T, %), absorption (e.g., A, %), or intensity (I, rel. units).
Photographs should be submitted in exceptional cases (provide schematic line diagrams whenever possible instead). Photographs should be clear, of highcontrast, with well-resolved details, and made on white glossy photographic paper.
All figures should be numbered by Arabic numerals in the order in which they are referred to in the text. The explanatory legends are provided with explanatory legends (list of captions) on a separate page. Captions describe the figures and explain lettering and other notation. All figures are obligatory referred to in the text (e.g., Fig. 1) and indicated on the margin of the manuscript the first time they appear.
Each figure should be identified on the back, by its number, the name of the first author, and the journal; in cases where the orientation is ambiguous, indicate the top of the figure.


Tables should be provided with captions and numbered (e.g., Table 1) in the order they are referred to in the text. Avoid tables constructed as several-level headings with a single line of data (such data can be presented in the text). Columns should have simple headings (capitalized) with units (abbreviated). Common elements of column headings should be separated into common heading lines. Avoid including figures and structural formulas in table columns.

References and Footnotes 

References are numbered in the order they appear in the text (in square brackets) and listed at the end of the paper. Footnotes are also numbered consecutively in order of first appearance (to be placed on the same page) and printed double-spaced on a separate sheet at the end of the text. For the proper form, see recent issues of this journal.
In the list of references, author names are typed in the following order: initials with dots and surname, all spaced by one interval. All authors of the source cited are given unless their number is more than four; in the latter case, the third author’s name is followed by et al..
For journals, the paper title is not given; the list of authors is followed by (separated by commas) the journal title (abbreviated according to CASSI, single-word titles not abbreviated), volume number or issue number preceded by No. (if both volume and issue numbers are indicated, the latter is given in parentheses without interval), first page or page interval and year in parentheses.
1. T. I. Mukhanova, L. M. Alekseeva, E. F. Kuleshova et al., Khim.-Farm. Zh., 27(2), 60 – 65 (1993).
2. V. M. Lyubchanskaya and V. G. Granik, Khim. Geterotsikl. Soedin., No. 1, 40 – 45 (1993).
3. R. F. Abdulla and R. S. Brinkmayer, Tetrahedron, 35, 1675 – 1677 (1979).
For books, the list of authors is followed by (separated by commas) book title, publisher, city and year in parentheses, volume number (preceded by Vol., for many-volume editions), issue (No.) or chapter (Ch.) number, and page (p.) or page interval (pp.). Total number of pages is not indicated. For books representing collections of papers, the list of authors of a paper is followed by “in:” and the book title is followed by the list of editors and (ed.) or (eds.).
1. T. R. Ponomareva and O. M. Dronova, Antibacterial Cultures [in Russian], Meditsina, Moscow (1984), pp. 23 – 27.
2. Reviews of Plasma Physics, M. A. Leontovich (ed.), Consultants Bureau, New York (1975), Vol. 6, pp. 84 – 88.
3. G. W. Andersen, in: Peptides. Chemistry and Biochemistry, B. Weinstein and S. Lande (eds.), Marcel Dekker, New York (1970), pp. 225 – 266.
For some other editions such as abstracts and proceedings of conferences, dissertations, and patents (accompanied with reference to Chem. Abstr., Ref. Zh. Khim., or Byull. Izobret.), see examples:
1. G. A. Mokrushina, S. G. Alekseev, V. N. Charushin, et al., Proceedings of the 5th All-Union Conf. on the Chemistry of Nitrogen-Containing Heterocycles, Chernogolovka (1991), pp. 15 – 23.
2. Yu. A. Azev, V. N. Charushin, and O. N. Chupakhin, Abstracts of Papers. The 10th Interdisciplinary World Congress on Antimicrobial and Anticancer Drugs, Geneva (1992), Abstr. 31.
2. L. I. Bol’shakov, Author’s Abstract of Cand. Sci., (Biol.) Dissertation, Moscow (1991).
3. Jpn. Patent No. 69939; Chem. Abstr., 117, 137670x (1992).
References to unpublished papers and dissertations are not allowed. Authors are responsible for the correctness of references.



Manuscripts should be submitted online to http://chem.folium.ru/index.php/chem
This web-based manuscript management system offers easy and straightforward login and submission procedures. It also allows you to track the progress of manuscript review in real time.
Manuscripts not obeying the above rules may be returned for revision, correction, or abridging. Please return the revised manuscript promptly together with the initial variant.


Before a publication decision is made, your manuscript will be reviewed by at least two independent, anonymous peers in the field, in addition to the assigned editor. During the initial submission of your manuscript, you have the opportunity to suggest appropriate reviewers for your manuscript, as well as to list any to whom you are opposed. This phase of the review process typically takes about three to four weeks to complete.


The editor will use the reviewers’ comments and recommendations to assist him or her in making a publication decision for your manuscript. At this point, the manuscript may be rejected, be accepted as is, or require minor or major revisions. In all cases, you may have access to the reviewers’ comments.


If the editor returns your manuscript with the request for minor or major revisions, you will have 30 days to revise and return your manuscript. If you need longer than the 30 days to conduct additional research, you must contact your editor immediately in order to be granted an extension. You will be provided with reviewers’ comments and suggestions for revision in order to help you improve your manuscript.
After your revised manuscript is submitted, the editor and/or reviewers will review it again, and a new publication decision will be rendered. Revised manuscripts are not guaranteed acceptance; your revised manuscript may be rejected, be accepted, or require additional revisions.


If your paper is accepted, approximately two weeks later, you will receive an email from the production department alerting you that your page proofs are ready to be reviewed. Follow the instructions in this email to access your proofs and submit any changes. During this stage, you should proofread your paper for any typos, verify that all authors’ names and affiliations are accurate and spelled correctly, and confirm that all tables, figures, and formulas have been properly formatted. Authors are responsible for all statements in their work, including changes made by the copyeditor after a manuscript is accepted, so please review your proofs carefully.


All articles published in the journal will follow the Springer Online First production workflow, enabling publication on the SpringerLink website after receipt of author corrections to page proofs.


Finally, accepted papers will appear in a print issue of Pharmaceutical Chemistry Journal.


Investigations using experimental animals must state in the Methods section that the research adhered to the ’’Principles of Laboratory Animal Care’’ (NIH publication #85-23, revised in 1985). Investigation with human subjects must state in the Methods section that the research followed the tenets of the Declaration of Helsinki promulgated in 1964 and was approved by the institutional human experimentation committee or equivalent, and that informed consent was obtained.


For information about the publisher’s policies, go to

English Language Editing 

For editors and reviewers to accurately assess the work presented in your manuscript you need to ensure the English language is of sufficient quality to be understood. If you need help with writing in English you should consider:
  • Asking a colleague who is a native English speaker to review your manuscript for clarity.
  • Visiting the English language tutorial which covers the common mistakes when writing in English.
  • Using a professional language editing service where editors will improve the English to ensure that your meaning is clear and identify problems that require your review. Two such services are provided by our affiliates Nature Research Editing Service and American Journal Experts. Springer authors are entitled to a 10% discount on their first submission to either of these services, simply follow the links below.
Please note that the use of a language editing service is not a requirement for publication in this journal and does not imply or guarantee that the article will be selected for peer review or accepted.
If your manuscript is accepted it will be checked by our copyeditors for spelling and formal style before publication.


● 请一位以英语为母语的同事审核您的稿件是否表意清晰。
● 查看一些有关英语写作中常见语言错误的教程。
● 使用专业语言编辑服务,编辑人员会对英语进行润色,以确保您的意思表达清晰,并识别需要您复核的问题。我们的附属机构 Nature Research Editing Service 和合作伙伴 American Journal Experts 即可提供此类服务。


・プロの英文校正サービスを利用する。校正者が原稿の意味を明確にしたり、問題点を指摘し、英語の質を向上させます。Nature Research Editing Service とAmerican Journal Experts の2つは弊社と提携しているサービスです。Springer の著者は、いずれのサービスも初めて利用する際には10%の割引を受けることができます。以下のリンクを参照ください。


영어 원고의 경우, 에디터 및 리뷰어들이 귀하의 원고에 실린 결과물을 정확하게 평가할 수 있도록, 그들이 충분히 이해할 수 있을 만한 수준으로 작성되어야 합니다. 만약 영작문과 관련하여 도움을 받기를 원하신다면 다음의 사항들을 고려하여 주십시오:
• 귀하의 원고의 표현을 명확히 해줄 영어 원어민 동료를 찾아서 리뷰를 의뢰합니다.
• 영어 튜토리얼 페이지에 방문하여 영어로 글을 쓸 때 자주하는 실수들을 확인합니다.
• 리뷰에 대비하여, 원고의 의미를 명확하게 해주고 리뷰에서 요구하는 문제점들을 식별해서 영문 수준을 향상시켜주는 전문 영문 교정 서비스를 이용합니다. Nature Research Editing Service와 American Journal Experts에서 저희와 협약을 통해 서비스를 제공하고 있습니다. Springer 저자들이 본 교정 서비스를 첫 논문 투고를 위해 사용하시는 경우 10%의 할인이 적용되며, 아래의 링크를 통하여 확인이 가능합니다.
영문 교정 서비스는 게재를 위한 요구사항은 아니며, 해당 서비스의 이용이 피어 리뷰에 논문이 선택되거나 게재가 수락되는 것을 의미하거나 보장하지 않습니다.
원고가 수락될 경우, 출판 전 저희측 편집자에 의해 원고의 철자 및 문체를 검수하는 과정을 거치게 됩니다.

Read this Journal on Springerlink

For authors and editors

  • Journal Citation Reports®
    2016 Impact Factor
  • 0.445
  • Aims and Scope

    Aims and Scope


    Pharmaceutical Chemistry Journal is a monthly publication devoted to scientific and technical research on the creation of new drugs and the improvement of manufacturing technology of drugs and intermediates. International contributors cover the entire spectrum of new drug research, including:

    methods of synthesis;
    results of pharmacological, toxicological, and biochemical studies;
    investigation of structure - activity relationships in prediction of new compounds;
    methods and technical facilities used; and
    problems associated with the development of ecologically safe and economically feasible methods of industrial production.

    In addition, analytical reviews of the international literature in the field provide coverage of the most recent developments around the world.

    Pharmaceutical Chemistry Journal is a translation of the Russian journal Khimiko-Farmatsevticheskii Zhurnal. The Russian Volume Year is published in English from April.
    All articles are peer-reviewed.

  • Instructions for Authors

    Instructions for Authors


  • Resources for Journal Authors
  • Author Academy: Training for Authors
  • Copyright Information

    Copyright Information


    Copyright Information

    For Authors

    Submission of a manuscript implies: that the work described has not been published before (except in form of an abstract or as part of a published lecture, review or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all co-authors, if any, as well as – tacitly or explicitly – by the responsible authorities at the institution where the work was carried out.

    Author warrants (i) that he/she is the sole owner or has been authorized by any additional copyright owner to assign the right, (ii) that the article does not infringe any third party rights and no license from or payments to a third party is required to publish the article and (iii) that the article has not been previously published or licensed. The author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors. Transfer of copyright to Springer (respective to owner if other than Springer) becomes effective if and when a Copyright Transfer Statement is signed or transferred electronically by the corresponding author. After submission of the Copyright Transfer Statement signed by the corresponding author, changes of authorship or in the order of the authors listed will not be accepted by Springer.

    The copyright to this article, including any graphic elements therein (e.g. illustrations, charts, moving images), is assigned for good and valuable consideration to Springer effective if and when the article is accepted for publication and to the extent assignable if assignability is restricted for by applicable law or regulations (e.g. for U.S. government or crown employees).

    The copyright assignment includes without limitation the exclusive, assignable and sublicensable right, unlimited in time and territory, to reproduce, publish, distribute, transmit, make available and store the article, including abstracts thereof, in all forms of media of expression now known or developed in the future, including pre- and reprints, translations, photographic reproductions and microform. Springer may use the article in whole or in part in electronic form, such as use in databases or data networks for display, print or download to stationary or portable devices. This includes interactive and multimedia use and the right to alter the article to the extent necessary for such use.

    Authors may self-archive the Author's accepted manuscript of their articles on their own websites. Authors may also deposit this version of the article in any repository, provided it is only made publicly available 12 months after official publication or later. He/she may not use the publisher's version (the final article), which is posted on SpringerLink and other Springer websites, for the purpose of self-archiving or deposit. Furthermore, the Author may only post his/her version provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".

    Prior versions of the article published on non-commercial pre-print servers like arXiv.org can remain on these servers and/or can be updated with Author's accepted version. The final published version (in pdf or html/xml format) cannot be used for this purpose. Acknowledgement needs to be given to the final publication and a link must be inserted to the published article on Springer's website, accompanied by the text "The final publication is available at link.springer.com". Author retains the right to use his/her article for his/her further scientific career by including the final published journal article in other publications such as dissertations and postdoctoral qualifications provided acknowledgement is given to the original source of publication.

    Author is requested to use the appropriate DOI for the article. Articles disseminated via link.springer.com are indexed, abstracted and referenced by many abstracting and information services, bibliographic networks, subscription agencies, library networks, and consortia.

    For Readers

    While the advice and information in this journal is believed to be true and accurate at the date of its publication, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may have been made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

    All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher (respective the copyright owner if other than Springer). The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

    Springer has partnered with Copyright Clearance Center's RightsLink service to offer a variety of options for reusing Springer content. For permission to reuse our content please locate the material that you wish to use on link.springer.com or on springerimages.com and click on the permissions link or go to copyright.com, then enter the title of the publication that you wish to use. For assistance in placing a permission request, Copyright Clearance Center can be connected directly via phone: +1-855-239-3415, fax: +1-978-646-8600, or e-mail: info@copyright.com.

    © Springer Science+Business Media New York

Alerts for this journal


Get the table of contents of every new issue published in Pharmaceutical Chemistry Journal.